Cohort 2 (Prevalent GLP-1 RA Users) Cohort 2 members comprised the following categories of patients: prior GLP-1 RA users who switched from other GLP-1 RAs to dulaglutide or semaglutide during the patient selection time window (prior GLP-1 RA user but nave to dulaglutide and/or semaglutide) and prior users of dulaglutide and semaglutide who received dulaglutide or semaglutide during the patient selection window (prior GLP-1 RA user not nave to dulaglutide and/or semaglutide)
Participants, stratified by geographic region, T2D status and fibrosis stage, were randomized to receive semaglutide at a maximum dose of 0.1 mg ( n = 80), 0.2 mg ( n = 78) or 0.4 mg ( n = 82) or placebo ( n = 80) via once-weekly subcutaneous injection for 72 weeks
Enhanced weight loss When paired with diet and exercise, appetite suppressants can lead to significant weight reduction
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for the treatment of type 2 diabetes mellitus and chronic weight management
A 91/100 in Safety & Legitimacy, LegitScript certification, a clean disciplinary record, and a verifiable US address all mean the clinical fundamentals here are rock solid
